Trials / Recruiting
RecruitingNCT06717880
A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer
Phase I Study to Evaluate the Safety, Tolerability and Efficacy of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 260 (estimated)
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 1 study of IBI363 in combination with Bevacizumab or Furuitinib in Subjects with Advanced Colorectal Cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI363 combined with Bevacizumab | IBI363 will be administrated on Day 1 of every 2 weeks or every 3 weeks, intravenous injection. Bevacizumab, intravenous injection. |
| DRUG | IBI363 + Furuitinib | IBI363 Q2W or Q3W IV，Furuitinib po |
Timeline
- Start date
- 2023-07-28
- Primary completion
- 2025-07-31
- Completion
- 2026-07-31
- First posted
- 2024-12-05
- Last updated
- 2025-02-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06717880. Inclusion in this directory is not an endorsement.